Journal of Clinical Oncology, Vol 21, Issue 13
(July), 2003: 2558-2563
© 2003 American Society for Clinical Oncology
Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated With a Melanoma Vaccine
Robert A. Wascher,
Donald L. Morton,
Christine Kuo,
Robert M. Elashoff,
He-Jing Wang,
Mehri Gerami,
Dave S.B. Hoon
From the Department of Molecular Oncology, John Wayne Cancer Institute, Saint John’s Health Center, Santa Monica; and Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA.
Address reprint requests to Dave S.B. Hoon, PhD, Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404; email: hoond{at}jwci.org.
Purpose: Patients with American Joint Committee on Cancer (AJCC) stage III melanoma are at high risk of recurrence and death. We hypothesized that a multiple-marker reverse transcriptase polymerase chain reaction (MM-RT-PCR) blood assay could predict, early in the course of therapy, those patients destined to experience treatment failure with a melanoma vaccine (MV) previously shown to improve survival in a phase II clinical trial.
Patients and Methods: After complete surgical resection, prospectively collected cryopreserved peripheral-blood lymphocyte specimens (n = 90) from the serial bleeds of 30 patients with AJCC stage III melanoma were studied by MM-RT-PCR, using the markers tyrosinase, melanoma antigen recognized by T cells-1 (MART-1), and universal melanoma antigen gene-A (uMAG-A). All patients were enrolled in a phase II MV trial during the period of blood draws, and were selected for this study in a blinded fashion. Median duration of clinical follow-up was 74 months for the 13 survivors and 11 months for the 17 nonsurvivors.
Results: The presence of at least one melanoma-specific RT-PCR marker was associated with an increased risk of disease recurrence (risk rate, 3.12; P = .02) and decreased risk of survival (relative rate, 2.62; P = .0496) by multivariate analysis.
Conclusion: MM-RT-PCR of the blood provided early prediction of subsequent disease recurrence and death in clinically disease-free AJCC stage III melanoma patients enrolled in a MV phase II trial. On the basis of the results of this pilot study, the MM-RT-PCR blood assay should be considered as a clinically important monitoring tool for assessing patient response to adjuvant therapy, and in the surveillance of clinically disease-free patients for the earliest signs of recurrence.
Supported in part by National Institutes of Health, National Cancer Institute P01 Grants CA 29,605 and CA 12,528, Project II.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Kitago, K. Koyanagi, T. Nakamura, Y. Goto, M. Faries, S. J. O'Day, D. L. Morton, S. Ferrone, and D. S.B. Hoon
mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads
Clin. Chem.,
April 1, 2009;
55(4):
757 - 764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Koyanagi, A. J. Bilchik, S. Saha, R. R. Turner, D. Wiese, M. McCarter, P. Shen, L. Deacon, D. Elashoff, and D. S.B. Hoon
Prognostic Relevance of Occult Nodal Micrometastases and Circulating Tumor Cells in Colorectal Cancer in a Prospective Multicenter Trial
Clin. Cancer Res.,
November 15, 2008;
14(22):
7391 - 7396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mocellin, D. Hoon, A. Ambrosi, D. Nitti, and C. R. Rossi
The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis
Clin. Cancer Res.,
August 1, 2006;
12(15):
4605 - 4613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Scoggins, M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, B. S. Davidson, J. J. Sussman, et al.
Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma
J. Clin. Oncol.,
June 20, 2006;
24(18):
2849 - 2857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Koyanagi, T. Mori, S. J. O'Day, S. R. Martinez, H.-J. Wang, and D. S.B. Hoon
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
Cancer Res.,
June 15, 2006;
66(12):
6111 - 6117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, H.-J. Wang, R. M. Elashoff, H. Takeuchi, N. Umetani, et al.
Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial
J. Clin. Oncol.,
November 1, 2005;
23(31):
8057 - 8064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Wascher
Pitfalls in the Use of RT-PCR As a Prognostic Indicator in Melanoma
J. Clin. Oncol.,
June 1, 2005;
23(16):
3863 - 3864.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Koyanagi, C. Kuo, T. Nakagawa, T. Mori, H. Ueno, A. R. Lorico Jr, H.-J. Wang, E. Hseuh, S. J. O'Day, and D. S.B. Hoon
Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients
Clin. Chem.,
June 1, 2005;
51(6):
981 - 988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring
Molecular Diagnosis of Cutaneous Diseases
Arch Dermatol,
February 1, 2005;
141(2):
225 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wlodzimierz, P. Rutkowski, Z. I. Nowecki, J. Kulik, A. Nasierowska-Guttmejer, and J. A. Siedlecki
Detection of Melanoma Cells in the Lymphatic Drainage after Lymph Node Dissection in Melanoma Patients by Using Two-Marker Reverse Transcriptase-Polymerase Chain Reaction Assay
Ann. Surg. Oncol.,
November 1, 2004;
11(11):
988 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
